Treatment of patients with chronic myeloid leukaemia (CML) in the chronic or accelerated phase of the disease.
Treatment of patients with essential thrombocythemia or polycythemia vera with a high risk for thrombo-embolic complications.
Spectrila® (Recombinant Asparaginase)
10,000 IU solution for infusion
Spectrila® is indicated as a component of antineoplastic combination therapy for the treatment of acute lymphoblastic leukaemia (ALL) in paediatric patients from birth to 18 years and adults.
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
Powder for injection/infusion 1000mg, 5000mg
Treosulfan is indicated for the palliative treatment of epithelial ovarian cancer.
Orphan designation was granted by the European Commission Conditioning treatment prior to haematopoietic progenitor cell transplantation